SK Biopharmaceuticals Statistics

Total Valuation

SK Biopharmaceuticals has a market cap or net worth of KRW 9.33 trillion. The enterprise value is 9.29 trillion.

Market Cap	9.33T
Enterprise Value	9.29T

Important Dates

The next estimated earnings date is Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

SK Biopharmaceuticals has 78.31 million shares outstanding.

Shares Outstanding	78.31M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	12.54%
Float	28.06M

Valuation Ratios

The trailing PE ratio is 276.49 and the forward PE ratio is 90.08.

PE Ratio	276.49
Forward PE	90.08
PS Ratio	20.07
PB Ratio	27.60
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 296.59, with an EV/FCF ratio of -1,155.53.

EV / Earnings	274.82
EV / Sales	19.97
EV / EBITDA	296.59
EV / EBIT	n/a
EV / FCF	-1,155.53

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.56.

Current Ratio	1.64
Quick Ratio	1.18
Debt / Equity	0.56
Debt / EBITDA	3.58
Debt / FCF	-25.66
Interest Coverage	4.04

Financial Efficiency

Return on equity (ROE) is 7.41% and return on invested capital (ROIC) is 4.93%.

Return on Equity (ROE)	7.41%
Return on Assets (ROA)	3.47%
Return on Capital (ROIC)	4.93%
Revenue Per Employee	1.93B
Profits Per Employee	140.23M
Employee Count	241
Asset Turnover	0.64
Inventory Turnover	0.35

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +45.43% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+45.43%
50-Day Moving Average	102,770.00
200-Day Moving Average	91,638.00
Relative Strength Index (RSI)	67.92
Average Volume (20 Days)	431,489

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK Biopharmaceuticals had revenue of KRW 465.06 billion and earned 33.80 billion in profits. Earnings per share was 431.11.

Revenue	465.06B
Gross Profit	423.60B
Operating Income	40.41B
Pretax Income	15.24B
Net Income	33.80B
EBITDA	57.54B
EBIT	40.41B
Earnings Per Share (EPS)	431.11

Full Income Statement

Balance Sheet

The company has 286.45 billion in cash and 206.23 billion in debt, giving a net cash position of 80.22 billion or 1,024.31 per share.

Cash & Cash Equivalents	286.45B
Total Debt	206.23B
Net Cash	80.22B
Net Cash Per Share	1,024.31
Equity (Book Value)	371.52B
Book Value Per Share	4,318.88
Working Capital	230.36B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.75 billion and capital expenditures -1.29 billion, giving a free cash flow of -8.04 billion.

Operating Cash Flow	-6.75B
Capital Expenditures	-1.29B
Free Cash Flow	-8.04B
FCF Per Share	-102.64

Full Cash Flow Statement

Margins

Gross margin is 91.08%, with operating and profit margins of 8.69% and 7.27%.

Gross Margin	91.08%
Operating Margin	8.69%
Pretax Margin	3.28%
Profit Margin	7.27%
EBITDA Margin	12.37%
EBIT Margin	8.69%
FCF Margin	-1.73%

Dividends & Yields

SK Biopharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	0.36%
FCF Yield	-0.09%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK Biopharmaceuticals has an Altman Z-Score of 8.69.

Altman Z-Score	8.69
Piotroski F-Score	n/a